Efmody: Teaching Hydrocortisone to Tell the Time

Kasi Subbiah
1 day ago
9 min read

The body does not simply make cortisol; it keeps time with it.

CORTISOL, CIRCADIAN RHYTHMS & CHRONOTHERAPY

Why replacing cortisol is not only about giving the right hormone, but helping it arrive at the right moment.

Most medicines are judged by a familiar question: how much should we give? Hormones make the question more interesting. With hormones, timing can matter almost as much as dose. Cortisol is not meant to sit at one steady level all day. It follows a carefully choreographed 24-hour rhythm, beginning to rise while we are still asleep, reaching its high point around waking, and settling towards its lowest level near bedtime.

Conventional hydrocortisone replaces a hormone the body cannot make adequately, and it remains a reliable, life-preserving treatment. But an immediate-release tablet taken after waking cannot travel backwards in time to cover the hours before waking. Efmody is a modified-release form of hydrocortisone designed to address that missing piece of the clock.

The short version: Efmody contains familiar hydrocortisone in unfamiliar packaging. Its capsule delays release so that a bedtime dose can begin supplying cortisol during the early hours of the morning, closer to the body’s natural rhythm.

First, meet cortisol: the hormone with a timetable

Cortisol is often called the “stress hormone”, which is accurate in roughly the same way that calling a smartphone “a device for making calls” is accurate. It does that—but it leaves out quite a lot.

Cortisol helps maintain blood pressure and circulation, supports blood glucose when fuel is needed, influences immune activity, and helps the body respond to illness, injury and other demands. It also participates in the transition from sleep to wakefulness. We need enough cortisol to stay well, and considerably more when the body is under major physical stress.

Its timing is directed by the brain. The hypothalamus signals the pituitary gland; the pituitary releases ACTH; and ACTH tells the adrenal glands, which sit like small hats above the kidneys, to make cortisol. Cortisol then feeds back to the brain and pituitary to say, in effect, “Message received—you can turn the signal down now.” This is the hypothalamic-pituitary-adrenal, or HPA, axis.

The clock is not perfectly smooth. Cortisol is released in small pulses within the larger daily rhythm. Nevertheless, the broad pattern is consistent: low around sleep onset, rising from roughly 2–4 am, highest around waking, and gradually lower through the day. The rise begins before the alarm clock. The adrenal glands, rather smugly, already knew you were getting up.

What goes wrong in adrenal insufficiency?

In adrenal insufficiency, the body cannot produce enough cortisol. In primary adrenal insufficiency—including Addison’s disease—the problem lies mainly in the adrenal glands. In secondary or tertiary adrenal insufficiency, the difficulty lies higher up the signalling chain, in the pituitary, hypothalamus or suppression of the HPA axis after glucocorticoid treatment.

Whatever the starting point, the practical problem is similar: cortisol must be replaced. Without adequate replacement, people may experience fatigue, weakness, nausea, dizziness, low blood pressure and poor tolerance of illness. A severe shortage can cause an adrenal crisis, a medical emergency requiring immediate parenteral hydrocortisone and fluids.

Standard immediate-release hydrocortisone works promptly after it is swallowed, but it is also cleared relatively quickly. A person taking the first dose on waking may therefore spend the latter part of the night with very little circulating cortisol—precisely when the natural level would already be climbing. For some people, this may contribute to the familiar experience of waking as if the body has received the calendar invitation but not the energy to attend.

CAH: when the missing cortisol signal creates a second problem

Congenital adrenal hyperplasia, or CAH, adds another layer to the story. The commonest form results from deficiency of an enzyme called 21-hydroxylase. This creates a biochemical roadblock in the adrenal gland: the pathway cannot make cortisol normally.

The brain does not see the roadblock. It only sees insufficient cortisol. The pituitary therefore releases more ACTH, pressing the accelerator harder. The adrenal glands enlarge—the “hyperplasia” in the name—and steroid building blocks are diverted towards adrenal androgens. This can disturb growth, puberty, periods, fertility and other androgen-sensitive features.

Treatment has to achieve two things at once: replace the cortisol that is missing and reduce the excessive ACTH drive that fuels androgen production. That is a delicate balance. Too little glucocorticoid risks adrenal insufficiency and poor androgen control; too much over many years can contribute to weight gain, hypertension, diabetes, reduced bone density and other features of glucocorticoid excess.

Timing explains why CAH can be particularly challenging. During the early morning hours, cortisol should be rising and restraining ACTH. If replacement is absent overnight, ACTH can surge and stimulate 17-hydroxyprogesterone and androgen production before the morning tablet has even reached the starting line. Increasing or moving conventional steroid doses may suppress that surge, but sometimes at the cost of exposing the body to more steroid when natural cortisol would be low.

The central problem: In CAH, clinicians are not simply filling an empty cortisol tank. They are trying to quiet an overactive hormonal feedback loop without flooding the rest of the body with unnecessary glucocorticoid.

So what exactly does Efmody do differently?

Efmody contains hydrocortisone—the same molecule as cortisol—but its capsule is engineered for delayed and sustained release. The coating resists release in the stomach. After the bedtime dose passes into the intestine, hydrocortisone begins to appear several hours later, allowing cortisol exposure to rise towards dawn. A smaller morning dose helps support the daytime profile.

This approach is called chronotherapy: designing treatment around biological time. It is not a stronger steroid, nor a completely new hormone. The innovation is the delivery schedule. In simple terms, standard hydrocortisone says, “Here is cortisol now.” Efmody says, “Keep this safe and deliver it when morning physiology begins.”

Efmody is usually prescribed twice daily, with the larger share of the daily dose at bedtime and the remainder in the morning. The precise dose must be individualised and adjusted by an experienced clinician. Capsules should be swallowed intact because chewing them can alter the release pattern. Current instructions about food, dose timing and additional immediate-release hydrocortisone should always come from the prescribing team and the leaflet supplied with the medicine.

What has the research actually shown?

In congenital adrenal hyperplasia

A phase 3 study included 122 adults with classic 21-hydroxylase-deficient CAH. The trial did not meet its primary endpoint—the overall change in the 24-hour 17-hydroxyprogesterone profile at six months. That sentence matters and should not be hidden in the small print.

However, several findings suggested better control at clinically important times. At six months, morning 17-hydroxyprogesterone was within the study’s control range in 91% of participants receiving modified-release hydrocortisone, compared with 71% receiving standard therapy. Longer follow-up suggested that biochemical control could be maintained while the median daily hydrocortisone dose eventually fell to 20 mg. Menstrual restoration and pregnancies were also reported, although these were not the trial’s primary outcomes.

A later open-label follow-up reported a median treatment duration of four years. Steroid doses reduced and then remained stable, while measures of CAH control improved. This is reassuring, but open-label extensions cannot answer every question: people know what treatment they are taking, there is no continuing randomised comparison, and those who remain in a long-term study may differ from those who leave.

In primary adrenal insufficiency

The 2026 CHAMPAIN study studied 58 adults with primary adrenal insufficiency. Each participant received four weeks of Efmody’s development formulation, Chronocort, and four weeks of once-daily Plenadren, another modified-release hydrocortisone product, in random order. Both regimens supplied 25 mg of hydrocortisone per day, but only Chronocort was designed to restore the early-morning rise.

At 7 am, median cortisol was 417 nmol/L with Chronocort and 6 nmol/L with Plenadren. Several measures of fatigue, physical wellbeing and adrenal-specific quality of life favoured Chronocort. This supports the biological idea that early-morning cortisol matters to how some people feel—not merely to how attractive a hormone graph looks.

The limitations are equally important. The study was small, each treatment period lasted only four weeks, and the comparator was Plenadren rather than ordinary immediate-release hydrocortisone. It was also industry funded. The results are promising and clinically interesting, but they do not prove that every person with adrenal insufficiency will feel dramatically different, nor do they yet establish long-term benefits for cardiovascular health, bone health or survival.

A fair reading of the evidence: Efmody reproduces the early-morning cortisol rise far better than conventional daytime-only replacement. In CAH it can improve morning biochemical control; in primary adrenal insufficiency it has improved fatigue and quality-of-life measures in a short trial. The size of benefit for an individual remains something to test carefully, not promise in advance.

Who might reasonably discuss Efmody with an endocrinologist?

Efmody is licensed in the UK and European Union for adolescents aged 12 years and over and adults with adrenal insufficiency or CAH. Licensing means that regulators have judged the benefits and risks acceptable for the stated use; it does not mean that it is automatically the best first treatment for everyone.

Immediate-release hydrocortisone remains effective, familiar and considerably less expensive. Efmody may be worth discussing when persistent early-morning symptoms remain despite a carefully optimised conventional regimen; when CAH control is difficult without higher or longer-acting glucocorticoid exposure; or when the pattern of symptoms and biochemical results suggests that timing, rather than simply total dose, is the missing piece.

The decision should consider symptoms across the whole day, blood pressure, weight, electrolytes, glucose, bone health, sleep, menstrual or fertility goals, other medicines, gastrointestinal conditions, adherence and—particularly in CAH—appropriately timed 17-hydroxyprogesterone and androstenedione measurements. A single number rarely deserves to run an endocrine clinic by itself.

What Efmody does not change

A more physiological profile does not remove the diagnosis. People who depend on glucocorticoid replacement still need sick-day education, an NHS Steroid Emergency Card or relevant local equivalent, ready access to emergency injectable hydrocortisone where advised, and a clear plan for vomiting, severe infection, trauma, surgery and other major physical stress.

Efmody should never be stopped suddenly. During illness or stress, additional immediate-release or injected hydrocortisone may be required because a modified-release maintenance capsule cannot be expected to manage every emergency. Vomiting or diarrhoea may prevent reliable absorption; suspected adrenal crisis requires urgent treatment, not a thoughtful debate about capsule technology.

Monitoring still matters. Both under-replacement and over-replacement can cause harm. Interacting medicines may alter hydrocortisone exposure, and conditions affecting gastrointestinal movement can make modified release less predictable. In CAH, improved hormonal control may restore fertility—occasionally before anyone has had time to update the family calendar—so contraception and pregnancy plans deserve an early conversation.

Possible disadvantages and uncertainties

Efmody is substantially more expensive than standard hydrocortisone, and NHS access may vary by local formulary and clinical circumstances. The twice-daily schedule and the importance of preserving the capsule’s release characteristics require reliable adherence. Dose optimisation can take time, and symptoms during a change of regimen may reflect either too little or too much replacement.

Reported adverse effects include fatigue, headache, dizziness, nausea, abdominal discomfort, sleep disturbance, appetite or weight changes, mood symptoms and low potassium, among others. Many risks relate to hydrocortisone exposure itself rather than to the capsule alone. The aim remains the lowest dose that safely achieves the desired clinical response.

Finally, “more physiological” should not quietly become “perfectly physiological”. Healthy adrenal glands adjust cortisol minute by minute, generate pulses, and respond instantly to the unexpected. A capsule can imitate part of this orchestra, particularly the dawn movement, but it is not yet the conductor.

The questions worth asking at an appointment

What problem are we trying to solve? Persistent morning fatigue, unstable replacement, troublesome CAH biochemistry and glucocorticoid overexposure are related but not identical problems.

Is the current regimen genuinely optimised? Dose timing, adherence, interacting medicines, sleep disorders, anaemia, thyroid disease and other causes of fatigue should not be overlooked.

How will we judge whether Efmody is helping? Agree beforehand which symptoms, laboratory results and safety measures will be reviewed—and over what time period.

What is my sick-day and emergency plan? Changing the maintenance preparation must never create uncertainty about additional dosing, vomiting or emergency injection.

How will access and cost be managed? Availability may depend on local prescribing arrangements and the clinical justification for treatment.

A medicine built around dawn

The most interesting thing about Efmody is not that it gives hydrocortisone. Medicine has been doing that for decades. Its real idea is that replacement therapy should respect physiology: the identity of the hormone, the amount we give and the time at which the body expects it.

For some people, standard hydrocortisone already provides an excellent balance. For others—particularly those with difficult early mornings or challenging CAH control—the missing ingredient may not be “more steroid”. It may be better-timed steroid.

Efmody therefore represents a modest but important change in the question. Instead of asking only, “How much cortisol is enough?”, it asks, “Can we help cortisol arrive when the body is waiting for it?” In endocrinology, where timing is woven into almost every hormone we make, that is a question worth waking up for.

Important safety note: This article provides general education and does not replace individual medical advice. Never alter or stop glucocorticoid treatment without your prescribing team. If adrenal crisis is suspected, use the emergency plan you have been given and obtain urgent medical help.